Rexahn raises $5.3M for cancer drugs; Neuraltus seeks $30M for Lou Gehrig's development;

@FierceBiotech: Still popular: 10 top drugs in biopharma's late-stage pipeline. Feature | Follow @FierceBiotech

@JohnCFierce: Osiris exits stem cell business, sells unit to Mesoblast in $100M deal. News | Follow @JohnCFierce

@DamianFierce: In case you missed it, some thoughts on why med tech companies aren't riding the biotech IPO wave. Editor's Corner | Follow @DamianFierce

@EmilyMFierce: Compound halts neurodegeneration in mice. Story from FierceBiotech Research | Follow @EmilyMFierce

> Rexahn Pharmaceuticals ($RNN) has signed a deal to sell $5.3 million in securities through a direct offering, cash it'll use to develop the cancer drugs Archexin, RX-3117, and RX-5902. News

> Are this year's beneficiaries of the biotech IPO boom doomed to tank when investors' lock-up periods expire? OncoMed Pharmaceutials ($OMED) CEO Paul Hastings advises companies how to maintain value. Interview

> Bay Area biotech Neuraltus Pharmaceuticals is raising $30 million to fund a Phase II study of a treatment for Lou Gehrig's disease. More

Medical Device News

@FierceMedDev: Biotronik unveils next-gen MRI-safe ICDs. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: Quest Diagnostics warns that its Q3 numbers won't be meeting expectations. Blame reimbursement pressures, etc. More | Follow @MarkHFierce

@MichaelGFierce: Check out this week's FierceDrugDelivery newsletter! RNAi roundup & stem cell drug delivery action. Report | Follow @MichaelGFierce

> St. Jude Medical CEO knocks rival and regulatory climate, but also offers optimism. More

> Gov't shutdown halts FCC's wireless med tech certification. Item

> Bipartisan backing of device tax repeal threatened by gov't funding fight. Story

> German-U.S. team test intestinal tube implant to treat obesity. Article

Pharma News

@FiercePharma: Top 10 Drugmakers in Emerging Markets--our latest special report. Feature | Follow @FiercePharma

@EricPFierce: spent €39B on emerging markets deals over 4 years. It has 40 manufacturing sites in these countries. More | Follow @EricPFierce

@CarlyHFierce: Vivus and Auxilium sign marketing deal for ED drug Stendra in the U.S. and Canada. Article | Release | Follow @CarlyHFierce

> Fresenius punished distributor for selling its drug for executions. Report

> J&J, AstraZeneca take Zytiga to Japan. Article

> FDA signoff on Ranbaxy NJ plant may provide drugmaker relief. Story

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.